TNFSF10 and cancer: Early functional studies indicated that Apo2L/TRAIL has a potent ability to preferentially trigger apoptosis in a variety of tumour cell lines vs normal cells, highlighting its potential as a candidate therapeutic in cancer (Wiley et al, 1995; Pitti et al, 1996).